» Articles » PMID: 28070483

Increased Hippocampal Activation in ApoE-4 Carriers and Non-carriers with Amnestic Mild Cognitive Impairment

Overview
Journal Neuroimage Clin
Publisher Elsevier
Specialties Neurology
Radiology
Date 2017 Jan 11
PMID 28070483
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Increased fMRI activation in the hippocampus is recognized as a signature characteristic of the amnestic mild cognitive impairment (aMCI) stage of Alzheimer's disease (AD). Previous work has localized this increased activation to the dentate gyrus/CA3 subregion of the hippocampus and showed a correlation with memory impairments in those patients. Increased hippocampal activation has also been reported in carriers of the ApoE-4 allelic variation independently of mild cognitive impairment although these findings were not localized to a hippocampal subregion. To assess the ApoE-4 contribution to increased hippocampal fMRI activation, patients with aMCI genotyped for ApoE-4 status and healthy age-matched control participants completed a high-resolution fMRI scan while performing a memory task designed to tax hippocampal subregion specific functions. Consistent with previous reports, patients with aMCI showed increased hippocampal activation in the left dentate gyrus/CA3 region of the hippocampus as well as memory task errors attributable to this subregion. However, this increased fMRI activation in the hippocampus did not differ between ApoE-4 carriers and ApoE-4 non-carriers and the proportion of memory errors attributable to dentate gyrus/CA3 function did not differ between ApoE-4 carriers and ApoE-4 non-carriers. These results indicate that increased fMRI activation of the hippocampus observed in patients with aMCI is independent of ApoE-4 status and that ApoE-4 does not contribute to the dysfunctional hippocampal activation or the memory errors attributable to this subregion in these patients.

Citing Articles

Precuneus Activity during Retrieval Is Positively Associated with Amyloid Burden in Cognitively Normal Older 4 Carriers.

Fischer L, Molloy E, Binette A, Vockert N, Marquardt J, Pacha Pilar A J Neurosci. 2025; 45(6).

PMID: 39788739 PMC: 11800745. DOI: 10.1523/JNEUROSCI.1408-24.2024.


Cerebral hyperactivation across the Alzheimer's disease pathological cascade.

Corriveau-Lecavalier N, Adams J, Fischer L, Molloy E, Maass A Brain Commun. 2024; 6(6):fcae376.

PMID: 39513091 PMC: 11542485. DOI: 10.1093/braincomms/fcae376.


Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease.

Burton C, Chumin E, Collins A, Persohn S, Onos K, Pandey R Front Neurosci. 2024; 17:1336026.

PMID: 38328556 PMC: 10847229. DOI: 10.3389/fnins.2023.1336026.


Levetiracetam for the treatment of mild cognitive impairment in Parkinson's disease: a double-blind controlled proof-of-concept trial protocol.

Dissanayaka N, Pourzinal D, Byrne G, Yang J, McMahon K, Pontone G Pilot Feasibility Stud. 2023; 9(1):189.

PMID: 37993889 PMC: 10664284. DOI: 10.1186/s40814-023-01406-y.


Aging and Alzheimer's disease have dissociable effects on local and regional medial temporal lobe connectivity.

Hrybouski S, Das S, Xie L, Wisse L, Kelley M, Lane J Brain Commun. 2023; 5(5):fcad245.

PMID: 37767219 PMC: 10521906. DOI: 10.1093/braincomms/fcad245.


References
1.
Buschke H, Fuld P . Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974; 24(11):1019-25. DOI: 10.1212/wnl.24.11.1019. View

2.
Celone K, Calhoun V, Dickerson B, Atri A, Chua E, Miller S . Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006; 26(40):10222-31. PMC: 6674636. DOI: 10.1523/JNEUROSCI.2250-06.2006. View

3.
Wilson I, Gallagher M, Eichenbaum H, Tanila H . Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci. 2006; 29(12):662-70. PMC: 2614702. DOI: 10.1016/j.tins.2006.10.002. View

4.
Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon S . Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci. 2010; 30(41):13707-17. PMC: 2988475. DOI: 10.1523/JNEUROSCI.4040-10.2010. View

5.
Dieguez Jr D, Barea-Rodriguez E . Aging impairs the late phase of long-term potentiation at the medial perforant path-CA3 synapse in awake rats. Synapse. 2004; 52(1):53-61. PMC: 1913478. DOI: 10.1002/syn.20004. View